Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial

Egils Vjaters; Saad F; Fizazi K; Jinga V; Efstathiou E; Fong PC; Hart LL; Hartmann Wilfried; Jones R; McDermott R; Thomas Wirth; Wirth M; Suzuki K

doi:10.1016/S1470-2045(15)70027-6

Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial

Egils Vjaters
, Saad F
, Fizazi K
, Jinga V
, Efstathiou E
, Fong PC
, Hart LL
, Hartmann Wilfried
, Jones R
, McDermott R
, Thomas Wirth
, Wirth M
, Suzuki K

Research output: Contribution to journal › Article › peer-review

116 Citations (Scopus)

Original language	English
Pages (from-to)	338-348
Journal	Lancet Oncology
Volume	16
Issue number	3
DOIs	https://doi.org/10.1016/S1470-2045(15)70027-6
Publication status	Published - 2015

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

OECD Field of Science

3. Medical and Health Sciences

Access to Document

10.1016/S1470-2045(15)70027-6

Cite this

Vjaters, E., F, S., K, F., V, J., E, E., PC, F., LL, H., Wilfried, H., R, J., R, M., Wirth, T., M, W., & K, S. (2015). Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial. Lancet Oncology, 16(3), 338-348. https://doi.org/10.1016/S1470-2045(15)70027-6

@article{df440f47212a42a3877546410b74b3f0,

title = "Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial",

author = "Egils Vjaters and Saad F and Fizazi K and Jinga V and Efstathiou E and Fong PC and Hart LL and Hartmann Wilfried and Jones R and McDermott R and Thomas Wirth and Wirth M and Suzuki K",

year = "2015",

doi = "10.1016/S1470-2045(15)70027-6",

language = "English",

volume = "16",

pages = "338--348",

journal = "Lancet Oncology",

issn = "1470-2045",

number = "3",

}

Vjaters, E, F, S, K, F, V, J, E, E, PC, F, LL, H, Wilfried, H, R, J, R, M, Wirth, T, M, W & K, S 2015, 'Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial', Lancet Oncology, vol. 16, no. 3, pp. 338-348. https://doi.org/10.1016/S1470-2045(15)70027-6

TY - JOUR

T1 - Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial

AU - Vjaters, Egils

AU - F, Saad

AU - K, Fizazi

AU - V, Jinga

AU - E, Efstathiou

AU - PC, Fong

AU - LL, Hart

AU - Wilfried, Hartmann

AU - R, Jones

AU - R, McDermott

AU - Wirth, Thomas

AU - M, Wirth

AU - K, Suzuki

PY - 2015

Y1 - 2015

UR - http://www.sciencedirect.com/science/article/pii/S1470204515700276

U2 - 10.1016/S1470-2045(15)70027-6

DO - 10.1016/S1470-2045(15)70027-6

M3 - Article

SN - 1470-2045

VL - 16

SP - 338

EP - 348

JO - Lancet Oncology

JF - Lancet Oncology

IS - 3

ER -

Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial

UN SDGs

OECD Field of Science

Access to Document

Other files and links

Cite this